All In Biotech

Drug Trial Radar · NCT06862206

A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Jul 11, 2025

Primary completion

Jan 31, 2028

Study completion Jan 31, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 6, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Conditions

  • Severe Eosinophilic Asthma

Interventions

  • benralizumabDrug

    non-interventional

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. asthma control questionnaireTime frame: Week 4

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Anning, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Binzhou, China · Recruiting

  • Research Site

    Changzhou, China · Recruiting

  • Research Site

    Fenyang, China · Recruiting

  • Research Site

    Guangdong, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Hefei, China · Recruiting

  • Research Site

    Huzhou, China · Recruiting

  • Research Site

    Jiaxing, China · Recruiting

  • Research Site

    Jinan, China · Recruiting

  • Research Site

    Jinhua, China · Recruiting

  • Research Site

    Jining, China · Recruiting

  • Research Site

    Jiyuan, China · Recruiting

  • Research Site

    Kunshan, China · Recruiting

  • Research Site

    Linyi, China · Recruiting

  • Research Site

    Mianyang, China · Recruiting

  • Research Site

    Nanbu, China · Recruiting

  • Research Site

    Nanchang, China · Recruiting

  • Research Site

    Nanjing, China · Recruiting

  • Research Site

    Ningbo, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanxi, China · Recruiting

  • Research Site

    Shenzhen, China · Recruiting

  • Research Site

    Shijiazhuang, China · Recruiting

  • Research Site

    Suining, China · Recruiting

  • Research Site

    Taiyuan, China · Recruiting

  • Research Site

    Weifang, China · Recruiting

  • Research Site

    Wuhan, China · Recruiting

  • Research Site

    Wuxi, China · Recruiting

  • Research Site

    Xi'an, China · Recruiting

  • Research Site

    Xiamen, China · Recruiting

  • Research Site

    Zhangjiagang, China · Recruiting

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Zhenjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.